JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Phase 2

Active, not recruiting

Conditions: Urothelial Cancer

Interventions: Drug: Erdafitinib
Drug: Midazolam
Drug: Metformin

First Posted Date: 2015-02-19

Last Posted Date: 2024-12-05

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 239

Registration Number: NCT02365597

A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-54861911 (Treatment A)
Drug: JNJ-54861911 (Treatment B)
Drug: JNJ-54861911 (Treatment C)

First Posted Date: 2015-02-04

Last Posted Date: 2017-03-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 12

Registration Number: NCT02355561

Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB

Phase 2

Recruiting

Conditions: Multidrug-Resistant Tuberculosis

Interventions: Drug: Bedaquiline (TMC207)
Drug: Background Regimen (BR)

First Posted Date: 2015-02-03

Last Posted Date: 2024-12-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 60

Registration Number: NCT02354014

Locations: 🇺🇦
State Institute Of Phthisiology And Pulmonology N.A. F.G. Yanovskiy Of Ams Ukraine, Kiev, Ukraine
🇺🇬
Makerere University Lung Institute, Kampala, Uganda
🇲🇿
Hospital Geral da Polana Caniço, Maputo, Mozambique

and more 5 locations

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

Phase 2

Completed

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: Ustekinumab IV
Drug: Placebo Infusion
Drug: Ustekinumab SC
Drug: Placebo SC
Other: Concomitant Medication

First Posted Date: 2015-01-28

Last Posted Date: 2020-03-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 102

Registration Number: NCT02349061

Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection

Phase 2

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: Simeprevir 150 mg
Drug: Daclatasvir 60 mg
Drug: Sofosbuvir 400 mg

First Posted Date: 2015-01-28

Last Posted Date: 2017-03-01

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 68

Registration Number: NCT02349048

Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly and and Healthy Younger Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Esketamine

First Posted Date: 2015-01-26

Last Posted Date: 2017-03-03

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 16

Registration Number: NCT02345148

A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis

Phase 1

Completed

Conditions: Atopic Dermatitis
Asthma
Healthy

First Posted Date: 2015-01-26

Last Posted Date: 2020-11-16

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 108

Registration Number: NCT02345928

A Study to Evaluate Use of Induced Skin Blisters in Adult Participants With Atopic Dermatitis, Allergic Asthma and Atopic Healthy Participants

Early Phase 1

Completed

Conditions: Asthma
Healthy
Dermatitis, Atopic

Interventions: Other: Allergic Skin Reaction (ASR) Testing and Skin Blister Induction

First Posted Date: 2015-01-22

Last Posted Date: 2015-10-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 46

Registration Number: NCT02343783

A Study to Evaluate the Absolute Bioavailability of Intranasal and Oral Esketamine and the Effects of Clarithromycin on the Pharmacokinetics of Intranasal Esketamine in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Esketamine
Drug: Clarithromycin

First Posted Date: 2015-01-21

Last Posted Date: 2015-09-28

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 18

Registration Number: NCT02343289

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Phase 2

Completed

Conditions: Influenza A

Interventions: Drug: Placebo
Drug: VX-787 300 mg
Drug: VX-787 600 mg
Drug: Oseltamivir 75 mg

First Posted Date: 2015-01-19

Last Posted Date: 2017-06-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 292

Registration Number: NCT02342249

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy